--- title: "Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month Low - What's Next?" type: "News" locale: "en" url: "https://longbridge.com/en/news/284286691.md" description: "Compass Therapeutics (NASDAQ:CMPX) shares hit a new 52-week low of $1.61, closing at $1.79 with significant trading volume. Analysts have mixed ratings: HC Wainwright maintains a \"buy\" with a $24 target, while Wall Street Zen downgraded to \"sell.\" The stock has a market cap of $322.36 million and a PE ratio of -4.16. Institutional investors hold 68.43% of shares. The company focuses on immuno-oncology therapies and reported an EPS of ($0.09), slightly above estimates. Analysts forecast a Moderate Buy rating with an average price target of $14.20." datetime: "2026-04-28T00:49:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284286691.md) - [en](https://longbridge.com/en/news/284286691.md) - [zh-HK](https://longbridge.com/zh-HK/news/284286691.md) --- # Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month Low - What's Next? Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Monday . The company traded as low as $1.61 and last traded at $1.79, with a volume of 157953676 shares trading hands. The stock had previously closed at $5.03. Get **Compass Therapeutics** alerts: ## Wall Street Analysts Forecast Growth - Top 3 High-Momentum Companies Analysts Are Still Bullish On A number of equities research analysts recently issued reports on the company. HC Wainwright reissued a "buy" rating and issued a $24.00 target price on shares of Compass Therapeutics in a research report on Monday. Wall Street Zen downgraded Compass Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. Guggenheim restated a "buy" rating and issued a $12.00 price target on shares of Compass Therapeutics in a research note on Tuesday, March 24th. William Blair reiterated an "outperform" rating on shares of Compass Therapeutics in a research report on Thursday, March 5th. Finally, Craig Hallum assumed coverage on Compass Therapeutics in a report on Friday, February 13th. They set a "buy" rating and a $15.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $14.20. **Read Our Latest Report on CMPX** ## Compass Therapeutics Stock Down 64.4% The company has a market capitalization of $322.36 million, a PE ratio of -4.16 and a beta of 1.49. The stock has a 50-day moving average of $5.46 and a 200 day moving average of $5.28. Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Thursday, March 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. Equities analysts forecast that Compass Therapeutics, Inc. will post -0.41 EPS for the current fiscal year. ## Institutional Inflows and Outflows Hedge funds and other institutional investors have recently bought and sold shares of the business. Flagship Harbor Advisors LLC purchased a new stake in shares of Compass Therapeutics in the 4th quarter worth approximately $32,000. Russell Investments Group Ltd. raised its holdings in Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company's stock worth $27,000 after purchasing an additional 7,592 shares during the period. Apollon Wealth Management LLC bought a new position in Compass Therapeutics in the 3rd quarter worth $35,000. Xponance LLC bought a new position in Compass Therapeutics in the 4th quarter worth $55,000. Finally, CIBC Bancorp USA Inc. bought a new stake in Compass Therapeutics during the third quarter valued at about $37,000. Institutional investors own 68.43% of the company's stock. ## Compass Therapeutics Company Profile (Get Free Report) Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment. The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells. ## See Also - Five stocks we like better than Compass Therapeutics _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Compass Therapeutics Right Now? Before you consider Compass Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list. While Compass Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md) ## Related News & Research - [Compass Therapeutics Inc. Tovecimig Plus Paclitaxel Improves Median Pfs To 4.7 Months Versus 2.6 Months](https://longbridge.com/en/news/284216233.md) - [Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained](https://longbridge.com/en/news/285256239.md) - [Pelthos Therapeutics GAAP EPS of -$3.09, revenue of $10.7M](https://longbridge.com/en/news/286430906.md) - [Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst](https://longbridge.com/en/news/286903837.md) - [LifeSci Capital Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)](https://longbridge.com/en/news/286679543.md)